Detection of Immuno Dominant Peptides against pgaB of Acinetobacter baumannii

M. Indumathi¹, A. S. Smiline Girija²*, P. Sankar Ganesh² and J. Vijayashree Priyadharsini²

¹Saveetha Dental College and Hospitals, SIMATS, Saveetha University, Chennai-600 077, Tamil Nadu, India.
²Department of Microbiology, Saveetha Dental College and Hospitals, SIMATS, Saveetha University, Chennai-600 077, Tamil Nadu, India.

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

ABSTRACT

Background: Acinetobacter baumannii is a gram negative non-motile coccobacillus, which was considered as a low priority pathogen with low virulence. Recently, it was declared as the priority pathogen under the critical category of the most dangerous pathogen by WHO. Acinetobacter Baumannii is an inhabitant of oral biofilms, and it also increases the risk of refractory periodontitis. It causes nosocomial infections with pgaB, a part of pgaABCD operon which is involved in the biofilm formation.

Aim: The aim of the present study was to detect the immunodominant peptides against pgaB of Acinetobacter baumannii using bioinformatic tools and databases.

Materials and Methods: The present study was carried out using immune informatics. The protein sequence of the pgaB protein from A.baumannii was subjected to assess allergenicity, secondary structure, antigenicity and stability prediction of selected T cell epitopes, physico-chemical analysis, Identification of MHC class 2 binders, Final selection of B-cell epitopes was done with IEDB B-cell epitope tool

Results: Final docking of the peptides were interpreted by hydrogen bonds and interaction scores with TLR-2. Promising scores on antigenicity, instability were obtained. Based on the combinatorial
scores, one vaccine peptide (LNLLTLGLAL) was suggested to be a promising vaccine candidate against pgaB of *A. baumannii.*

**Conclusion:** The findings of the present study suggest epitope LNLLTLGLAL as a promising vaccine candidate against pgaB of *A. baumannii.* The vaccine peptides targeting the pgaB Gene in *A. baumannii* using an immune-informatics approach suggests promising results in the present study. However, the predicted epitope peptides need further experimentation in animal models for its application against *A. baumannii.*

**Keywords:** Acinetobacter baumannii; novel pgaB; vaccine epitopes; environmental strains; innovative immune informatics.

1. INTRODUCTION

*Acinetobacter baumannii* is a gram negative non-motile coccobacillus, which was considered as a low priority pathogen with low virulence. Recently, it was declared as the priority pathogen under the critical category of the most dangerous pathogen by WHO. At present there are 32 species of *A. baumannii* [1]. *A. baumannii* causes recalcitrant nosocomial infections comprising respiratory, skin and wound, urinary tract infections leading to complicated septicemia [2]. Increase in the mortality rate is often documented in *A. baumannii* associated infections due to multidrug resistance (MDR) and extensive drug resistance (XDR) properties against various antibiotics. In addition to the resistance properties, it is also important to understand the association of various virulence factors playing an important role in transforming the pathogen into a priority pathogen [3].

*A. baumannii* contains a pgaABCD operon that codes the proteins related to poly-β-(1-6)-N-acetylglucosamine. Previous studies reported that pgaABCD operon in *A. baumannii* and numerous other gram positive and negative bacteria also encode PNAG [4]. The protein database sequence investigation by BLASTp search utilizing E. coli pgaABCD had reported a high similarity of *A. baumannii* gene loci associated with PNAG biosynthesis and 30 clinical isolates delivered recognizable PNAG [5]. pgaB being a part of pgaABCD operon consequently appears to be exceptionally associated with the biofilm arrangement in *A. baumannii* ascribing to its harmfulness and pathogenesis. A prior investigation on the expression level of pgaB depending on the cytotoxicity test in *A. baumannii* documented pgaB as an important early virulent marker [6].

Recent advances in immune informatics approaches could potentially decline the attrition rate and accelerate the process of vaccine development in these times. The 3D structure of the vaccine construct was designed, refined to obtain a high quality structure [7]. Then the refined structure was docked against Toll like receptors to confirm the interactions between them. Immune informatics analysis showed that the multi epitope vaccine can stimulate both T and B cells immune responses and it could potentially be used for therapeutic usages. Immune informatics will allow the vaccine development using non-conventional antigens. The process of vaccine discovery in silico using the genetic information is named as reverse vaccinology [8]. In the present study using immune informatics approach and reverse vaccinology, study has been done. The emergence of drug-resistant *Acinetobacter baumannii* is a worldwide health problem associated with high mortality rate. Therefore, it is important to find suitable therapeutics for this pathogen. The protocol was designed as per the previous literatures and based on the expertise of our studies done earlier [9–17]. The aim of the present study was to detect the immunodominant peptides against pgaB of *Acinetobacter baumannii* involved with the biofilm associated virulence using an immune informatics approach.

2. MATERIALS AND METHODS

2.1 Study Setting

This is an observational *in silico* study done in the department of Microbiology, Saveetha Dental College and Hospital.

2.1.1 Protein retrieval and evaluation of allergenicity

The sequence pgaB protein was retrieved from the Uniprot database and its sequence id was P59637. The Subcellular location was predicted as Host cell membrane using CELLO v.2.5: subCELlular LOcalization predictor tool. The allergenicity of pgaB protein was predicted using
AlgPred server which is a web server developed to predict allergenic proteins and for mapping IgE epitopes using motif-based method has been developed using MEME/MAST software.

### 2.2 Secondary Structure

The secondary structure of pgaB was predicted using the Self-Optimized Prediction Method with Alignment (SOPMA) server. The percentage of α-helix, beta sheet, turns and coils were predicted.

#### 2.2.1 Identification of MHC Class –II binders (T-cell epitopes)

T MHC class II molecules play an important role in initiation of the antigen-specific immune response. The T-cell epitopes of pgaB were predicted using the EpitDOCK server which predicts the binding of epitopes to 12 HLA-DR, 6 HLA-DQ, and 5 HLA-DP alleles. The first structure based server for the prediction of MHC class II binding using the Fasta format of sequence as input. Maximum number of epitopes binders (≥9) was identified and taken for further analysis.

#### 2.2.2 Antigenicity and stability prediction of selected T-cell epitopes

Antigenicity was predicted using Vaxigen v 2.0, instability index of predicted epitopes was calculated using protparam server.

#### 2.2.3 Predicted epitopes structure prediction and Validation

The structure predicted MHC Class – II binders were predicted using Pep Fold server which uses de novo approach to predict peptide structures from amino acid sequences. The structure predicted was validated using RAMPAGE tool which predicts the stereochemical properties of given structure. The server assesses the quality of modelled epitopes by predicting the amino acids falling in favoured, allowed and disallowed regions of Ramachandran plot.

#### 2.2.4 Molecular docking of epitopes with HLA-alleles and TLR-2 receptor using cluster pro server

The three-dimensional structures of HLA-DP - 3LQZ, HLA-DQ - 5KSV, HLA-DR - 4AH2, TLR-2-6NIG were retrieved from the PDB database. The molecular docking analysis of predicted MHC binders with HLA-Alleles were carried out using Clusterpro Server.

### 2.2.5 B cell epitope prediction

The B cell Epitope prediction of E-protein was carried out using Immune Epitope Database (IEDB) using Kolaskar & Tongaonkar Antigenicity Prediction method.

### 3. RESULTS

#### 3.1 Protein Retrieval and Evaluation of Allergenicity

The sequence pgaB protein was retrieved from Uniprot database and its sequence id was P59637. The Subcellular location was predicted as a Periplasmic region. The protein was predicted as non-allergen with a Score=-0.4161328 predicted by SVM method based on amino acid composition.

#### 3.2 Secondary Structure

Using the SOPMA server, the secondary structure was predicted. The percentage of alpha helix, extended strand, beta turn and random coil were given in (Table 1).

#### 3.2.1 Identification of MHC Class –II binders (T-cell epitopes)

From epi dock server, 13 epitopes were selected based on the maximum number binders to HLA-DP, DQ, and DR (Table 2).

#### 3.2.2 Antigenicity and stability prediction of selected T-cell epitopes

Antigenicity was predicted using Vaxijen v2.0, instability index of predicted epitopes was calculated using protparam server. vaxijen scores for the following sequence were: MITRFASPL= -0.6592, ITRFASPLL =-0.7111, FASPLLNLT= 0.0541, ASTLTVIGY=0.0771, EITDTKNAL=0.2101, TKNALIPQY=0.3381. Protparam scores were: MITRFASPL, ITRFASPLL and FASPLLNLT these sequences had 57.71 score (Table 2).

#### 3.2.3 Predicted epitopes structure prediction and validation

The stereo chemical properties were validated using RAMPAGE TOOL. This server will assess the quality of modelled epitopes by predicting the
amino acids falling in favoured, allowed and disallowed regions of Ramachandran plot. It is amazing to see that epitope 2, epitope 3, epitope 4 and epitope 6 with the sequence of LTLGLALAG, LGLALAGLS, LAGLSGMAL, IGYHEITDT respectively possessed 100% most favourable regions (Fig. 1) and epitope 1 with the sequence of LNLTLGLAL possessed 85.7% most favourable region (Table 3).

3.2.4 Molecular docking of epitopes with HLA-alleles and TLR-2 receptor using cluster pro server

Epitope 1 with sequence LNLTLGLAL, had the following scores HLA-DP = -732.1, HLA-DQ = -636.2, HLA-DR = -661.2 and TLR-2 = -1120.1 (Table 5). There is a strong molecular docking for the TLR-2 with the score of -1120.1. This is according to the greater the negative score, higher will be the molecular docking (Table 4).

3.2.5 Docking interactions of NLTLGLAL with HLA-DP, HLA-DQ, HLA-DR and TLR 2

Final docking of the peptides were interpreted by hydrogen bonds and interaction scores with TLR-2 (Table 5, 6, 7 & 8). The docking interaction of NLTLGLAL with HLA-DP, HLA-DQ, HLA-DR and TLR-2 is given in (Fig. 2).

3.2.6 B cell epitope prediction

In the B cell epitope prediction, B cell antigenic epitope prediction from the pgaB of Acinetobacter baumannii with the start and end position showing the antigenic peptide sequences as a yellow colour peak (Fig. 3).

Table 1. Percentage of predicted secondary structure of pgaB

| Structure       | Percentage |
|-----------------|------------|
| Alpha helix     | 45.03%     |
| Extended strand | 13.70%     |
| Beta turn       | 5.12%      |
| Random coil     | 36.14%     |

Table 2. Identification of MHC Class –II binders (T-cell epitopes), antigenicity and Stability prediction of selected T-cell epitopes

| Position of peptide | Position of peptide | Sequence     | Number of binders to HLA alleles (DP, DQ, DR) | Vaxijen v 2.0 | Protparam |
|---------------------|---------------------|--------------|-----------------------------------------------|--------------|----------|
| 1                   | 1                   | MITRFASPL    | 12                                            | -0.6592      | 57.71    |
| 2                   | 2                   | ITRFASPLL    | 16                                            | -0.7111      | 57.71    |
| 5                   | 5                   | FASPLLNLT    | 9                                             | 0.0541       | 57.71    |
| 10                  | 10                  | LNLTLGLAL    | 15                                            | 1.5726       | 8.89     |
| 12                  | 12                  | LTLGLALAG    | 9                                             | 0.9952       | 8.89     |
| 14                  | 14                  | LGLALAGLS    | 10                                            | 0.6771       | 22.60    |
| 18                  | 18                  | LAGLSGMAL    | 14                                            | 0.4877       | 22.60    |
| 31                  | 31                  | KIDASTLTV    | 9                                             | 1.3569       | -0.54    |
| 34                  | 34                  | ASTLTVIGY    | 10                                            | -0.0771      | -0.54    |
| 40                  | 40                  | IGYHEITDT    | 11                                            | 0.7789       | 17.87    |
| 44                  | 44                  | EITDTKNAL    | 9                                             | 0.2101       | 13.59    |
| 48                  | 48                  | TKNALIPQY    | 9                                             | 0.3381       | 18.71    |
| 52                  | 52                  | LIPQYAVTT    | 11                                            | 0.9690       | 35.59    |

Table 3. Predicted Epitopes structure prediction and Validation using the Rampage tool

| Peptides  | Most favoured region | Additional allowed region | Generously allowed region | Disallowed region |
|-----------|----------------------|---------------------------|---------------------------|-------------------|
| Epitope 1 | LNLTLGLAL            | 85.7%                     | 16.7%                     | -                 |
| Epitope 2 | LTLGLALAG            | 100%                      | -                         | -                 |
| Epitope 3 | LGLALAGLS            | 100%                      | -                         | -                 |
| Epitope 4 | LAGLSGMAL            | 100%                      | -                         | -                 |
| Epitope 5 | KIDASTLTV            | 71.4%                     | 28.6%                     | -                 |
| Epitope 6 | IGYHEITDT            | 100%                      | -                         | -                 |
| Epitope 7 | LIPQYAVTT            | 71.4%                     | 28.6%                     | -                 |
Table 4. Molecular Docking of epitopes with HLA-alleles and TLR-2 Receptor

| Epitope | HLA-DP    | HLA-DQ    | HLA-DR    | TLR-2    |
|---------|-----------|-----------|-----------|----------|
| 1       | LNLTLGLAL | -732.1    | -636.2    | -661.2   | -1120.1  |
| 2       | LTGLALAG  | -715.4    | -617.6    | -660.5   | -944.5   |
| 3       | LGLALAGLS | -679.6    | -580.2    | -645.8   | -960.8   |
| 4       | LAGLSGMAL | -631.7    | -539.9    | -598.5   | -899.7   |
| 5       | IGYHEITDT | -653.6    | -559.0    | -621.4   | -860.9   |

Table 5. Docking interactions of LNLTLGLAL with HLA-DP

| Interactions          | LnLTLGLAL | HLA-DP | Distance (Å) |
|-----------------------|-----------|--------|--------------|
| Hydrogen bond         | LEU1      | HT1    | 2.82         |
|                       | ASN2      | HN     | 3.03         |
| Hydrophobic pi-sigma  | LEU9      | C      | 3.19         |
| Alkyl/Alkyl           | ASN2      | CA     | 3.69         |
|                       | LEU3      | ALA82  | 4.33         |
|                       | LEU9      | LEU66  | 4.42         |
|                       | ALA8      | LEU70  | 4.24         |

Table 6. Docking interactions of LNLTLGLAL with HLA-DQ

| Interactions          | LnLTLGLAL | HLA-DQ (atom) | Distance (Å) |
|-----------------------|-----------|---------------|--------------|
| Hydrogen bond         | LEU7      | O             | 2.08         |
|                       | THR4      | HG1           | 1.91         |
|                       | THR4      | HG1           | 2.39         |
|                       | ASN2      | HD22          | 2.03         |
|                       | ASN2      | OD1           | 2.47         |
|                       | ASN2      | OD1           | 2.16         |
|                       | LEU1      | O             | 1.95         |
|                       | LEU1      | O             | 2.81         |
| Hydrophobic Alkyl     | LEU1      | O             | 5.37         |
|                       | LEU7      | O             | 4.59         |

Table 7. Docking interactions of LNLTLGLAL with HLA-DR

| Interactions          | LnLTLGLAL | HLA-DR | Distance (Å) |
|-----------------------|-----------|--------|--------------|
| Hydrogen bond         | ASN2      | HD22   | 2.01         |
|                       | ASN2      | HD21   | 2.69         |
|                       | LEU1      | O      | 2.77         |
|                       | ASN2      | HD22   | 2.09         |
|                       | ASN2      | HD21   | 2.21         |
|                       | THR4      | HG1    | 3.02         |
|                       | THR4      | OG1    | 1.92         |
| Hydrophobic Alkyl     | LEU1      | O      | 1.91         |
|                       | LEU3      | O      | 4.66         |
|                       | ALA8      | O      | 5.33         |
|                       | ALA8      | O      | 5.01         |
|                       | LEU9      | O      | 5.46         |
| Hydrophobic Pi-sigma  | THR4      | O      | 3.87         |
| Electrostatic         | LEU1      | N      | 4.56         |
Table 8. Docking interactions of LNLTLGLAL with TLR-2

| Hydrogen bond          | Residue | atom  | TLR-2 | atom  | Distance (Å) |
|------------------------|---------|-------|-------|-------|--------------|
| Hydrogen Classical     | ASN2    | HD22  | LEU331| O     | 2.85         |
| Hydrogen Classical     | ASN2    | HD22  | THR335| OG1   | 1.91         |
| Carbon hydrogen        | LEU9    | C     | SER346| O     | 2.79         |
| Carbon hydrogen        | LEU1    | -     | PRO306| -     | 5.12         |
| Carbon hydrogen        | LEU1    | -     | VAL309| -     | 4.04         |
| Hydrophobic Alkyl/Pi-Alkyl | LEU3   | -     | MET270| -     | 4.91         |
| Hydrophobic Alkyl/Pi-Alkyl | LEU3   | LEU282|       |       | 4.91         |
| Hydrophobic Alkyl/Pi-Alkyl | LEU3   | PHE284|       |       | 4.53         |
| Hydrophobic Alkyl/Pi-Alkyl | LEU3   | LEU266|       |       | 5.22         |
| Hydrophobic Alkyl/Pi-Alkyl | LEU7   | PHE284|       |       | 5.10         |
| Hydrophobic Alkyl/Pi-Alkyl | LEU7   | ILE314|       |       | 4.16         |
| Hydrophobic Alkyl/Pi-Alkyl | LEU7   | LEU289|       |       | 4.59         |
| Hydrophobic Alkyl/Pi-Alkyl | LEU7   | LEU317|       |       | 4.59         |
| Hydrophobic Alkyl/Pi-Alkyl | LEU5   | TYR332|       |       | 4.74         |
| Hydrophobic Alkyl/Pi-Alkyl | LEU9   | VAL348|       |       | 4.37         |
| Hydrophobic Alkyl/Pi-Alkyl | LEU1   | VAL338|       |       | 5.23         |
| Hydrophobic Alkyl/Pi-Alkyl | ALA8   | TYR326|       |       | 4.99         |

Fig. 1. These epitopes LTLGLALAG, LGLALAGLS, LAGLSGMAL and IGYHEITDT showed 100% most favourable region in the Ramachandran plot.
Fig. 2. Molecular docking interactions of LNLTLGLAL with HLA DP, HLA DQ, HLA DR and TLR 2

Fig. 3. B-cell antigenic epitope predictions from pgaB of A.baumannii with the start and end positions showing the antigenic peptide sequences (as an yellow colour peak).
4. DISCUSSION

*Acinetobacter baumannii* possess multi-drug resistant properties due to this property, it causes serious diseases and its colonies mainly in the hospitalized patients. Discovering new methods to combat the infections caused by *A. baumannii* seems to be the need of the hour. Considering the treatment and prevention of diseases caused by *A. baumannii*, the best alternate method is discovery of vaccines [18]. Considering this, the present study was designed as an observational and evaluation of vaccine candidates against the pgaB of *A. baumannii* and to arrest the formation of biofilms. While constructing a vaccine, the selection of B-cell and T-cell dominant epitopes is an important step because it should significantly bind with the immunological receptors and is considered to be an important step to provoke both humoral and cell-mediated immune responses in the host. Detection of promiscuous pgaB vaccine peptides was thus successfully achieved in the present study by the immuno-informatics approach utilizing the available genomic and proteomic reservoirs under a single computational platform comprising various databases and tools [19].

The selection of specific protein is the initial step in vaccine peptide analysis. The selection of protein was good and the sequence pgaB protein was retrieved from the uniprot database. The subcellular location was also determined. The protein was predicted as non-allergen with a score = -0.41611328. It is important that the protein should be a non-allergen. If the protein possesses an allergen, it will cause an allergic reaction in the host. The most immediate reactions are Type I hypersensitivity reactions which are mediated by the interaction of IgE antibodies against a particular vaccine component. These reactions occur within minutes of exposure to the relevant allergen and almost always occur within 4 hours of exposure to the relevant allergen, however, possible exceptions for delayed-onset reactions also do occur. Thus the preliminary predictions on allergenicity would be promising in the detection of possible epitopes that can be utilized for the vaccine development [20].

The secondary structure of pgaB was predicted and the percentage of alpha helix, beta sheet, turns and coils were predicted. The secondary structure of the protein can also determine protein topology. SOPMA is a server tool to detect and identify the percentage of secondary structure of a protein. It works based on the primary sequence of a protein. Combination of SOPMA and neural network methods have correctly predicted 82.2% of residues for 74% of predicted amino acids together with the Ramachandran plot showing more structural similarity of the residues and were thus validated [21].

To assess the epitopes to evoke cellular immunity, MHC class 2 binders T cell epitopes were predicted using an epidock server. 13 epitopes were selected based on the maximum number of binders. HLA-DQ, HLA-DP and HLA-DR, these haplotypes along with their multiple subtypes have been survived so many infectious episodes in human history because of their ability to present pathogenic peptides to activate T cells that secrete cytokines to clear infections [22].

In the Ramachandran plot, epitope 2, 3, 4 & 6 possess 100% most favoured regions which were structurally correlated with the structure which was predicted early. Ramachandran plot can be used for structure validation.

According to the molecular docking of epitopes with HLA - alleles of TLR - 2 receptor, the epitope 1 LNLTLGLAL, for HLA - DP = -732.1, of HLA-DQ = - 636.2 HLA- DR = -661.2 and for TLR - 2 = -1120.1. There is a strong molecular docking for the TLR - 2 with the score of -1120.1. This is according to the greater the negative score, higher will be the affinity towards the interactions. Molecular docking is a tool in structural molecular biology and computer assisted drug design. Docking can be used to perform initial screening of results and it can also propose structural hypotheses on having the ligands inhibit the target. The two main factors for a successful docking experiment are convert pose and affinity prediction. Molecular docking is utilized in structure based drug design, biochemical pathway & to drug designing being the most attractive tools and the same has been applied to analyze the interaction energies [23].

In order to involve humoral immune response, it is essential to predict the vaccine epitope. In the present study we also performed the B cell epitope evaluation at threshold 1.020, starting & reading position sharing antigenic peptide sequence as yellow colour peaks. B cell epitopes are antigenic determinants that are recognized and bound by receptors on the surface of B lymphocytes. The identification of the constitution of B cell epitopes play an important role in
vaccine design and in correlation with this, the present study has predicted the possible B cell dominant epitopes from pgaB.

Our team has extensive knowledge and research experience that has translated into high quality publications [24–27]. The immune-informatic approach holds very promising for marine sources and also for the synthetic chemicals [28, 29]. Homology modelling of the predicted peptides is an easiest method to be considered for both the drug and vaccine design [30]. Bio-informatic approach also holds good for the prediction of resistant determinants from oro-dental pathogens and also in other systemic diseases [31 – 34]. Thus in the present investigation, epitope LNLTGLAL is predicted as a promising vaccine candidate against pgaB of A.baumannii. The limitation of the study was that the predictions were done only using in-silico tools. However, the future prospects are set to experimentally evaluate the same in animal models for its application against A.baumannii associated infections.

5. CONCLUSION
An attempt to detect few vaccine peptides targeting the pgaB in A baumannii using an immune - informatic approach in the present study had documented promising results. Epitope LNLTGLAL is predicted as a good vaccine candidate against pgaB of A.baumannii. However further experimental evaluation on its immunological memory and responses are needed to be analyzed for its applicability as vaccine peptides. In addition, the prediction of epitope peptides using an immune informatics approach and reverse vaccinology technique aid in the detection of novel vaccine peptides with minimal error in comparison with the conventional method. From the available vaccine peptide data, it is evident to construct a vaccine against the pgaB of Acinetobacter baumannii.

DISCLAIMER
The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors. The authors are grateful for the support by Saveetha Institute of Medical and Technical Sciences [SIMATS], Saveetha Dental College, Saveetha University, Chennai and Sarkav Health Services.

ETHICAL APPROVAL
Institutional approval for the research was obtained (IHEC/SDC/UG-1963/21/146).

ACKNOWLEDGEMENT
The authors would like to thank the management of Saveetha Dental College for providing the opportunity to undertake this project.

COMPETING INTERESTS
Authors have declared that no competing interests exist.

REFERENCES
1. Chang D, Garcia R, Akers KS, Wenke J, Sanchez C. Activity of Gallium (III) Compounds Against Biofilms of Multidrug-Resistant Isolates of Acinetobacter baumannii. Open Forum Infectious Diseases. 2015;2.
2. Whitaker JL. MDR Acinetobacter baumannii in the short term and long term acute care setting. Vol. 5, BMC Proceedings;2011.
3. Averhoff B. Acinetobacter baumannii — understanding and fighting a new emerging pathogen. Vol. 7, Environmental Microbiology Reports. 2015;6–8.
4. Han S. Crystal structure of Acinetobacter baumannii PBP1A in complex with MC-1; 2011.
5. Roy R, Panigrahi P, Malathi J, Pal SS, Nandi K, Patil A, et al. Endophthalmitis caused by Acinetobacter baumannii: a case series. Eye. 2013;27:450–2.
6. Bahar İ, Elay G. Is there a mortality effect of empiric colistin in the treatment of acinetobacter baumannii?. Vol. 24, Eastern Journal Of Medicine. 2019;405–11.
7. Hosseini SS, Aghaiypour Kolyani K, Rafiei Tabatabaei R, Goudarzi H, Akhavan Sepahi A, Salemi M. prediction of B and T cell epitopes based on NDV fusion protein for vaccine development against Newcastle disease virus. Vet Res Forum. 2021;12(2):157–65.
8. Wang W, Liu J, Guo S, Liu L, Yuan Q, Guo L, et al. Identification of and spp. Specific
Outemembrane proteines by reverse vaccinology and surface proteome. Front Microbiol. 2020;11:625315.

9. Priyadharshini JV, Vijayashree Priyadharshini J, Smiline Girija AS, Paramasivam A. In silico analysis of virulence genes in an emerging dental pathogen A. baumannii and related species. Vol. 94, Archives of Oral Biology. 2018:93–8.

10. Vijayashree Priyadharshini J. In silico validation of the non-antibiotic drugs acetaminophen and ibuprofen as antibacterial agents against red complex pathogens. J Periodontol. 2019;90(12):1441–8.

11. Paramasivam A, Vijayashree Priyadharshini J, Raghunandhakumar S. N6-adenosine methylation (m6A): a promising new molecular target in hypertension and cardiovascular diseases. Hypertens Res. 2020;43(2):153–4.

12. Vijayashree Priyadharshini J, Smiline Girija AS, Paramasivam A. An insight into the emergence of Acinetobacter baumannii as an oro-dental pathogen and its drug resistance gene profile - An in silico approach. Heliyon. 2018;4(12):e01051.

13. Paramasivam A, Vijayashree Priyadharshini J. Novel insights into m6A modification in circular RNA and implications for immunity. Cell Mol Immunol. 2020;17(6):668–9.

14. Paramasivam A, Priyadharshini JV, Raghunandhakumar S. Implications of m6A modification in autoimmune disorders. Cell Mol Immunol. 2020;17(5):550–1.

15. Girija ASS, Shankar EM, Larsson M. Could SARS-CoV-2-Induced Hyperinflammation Magnify the Severity of Coronavirus Disease (CoVID-19) Leading to Acute Respiratory Distress Syndrome? Front Immunol. 2020;11:1206.

16. Jayaseelan VP, Arumugam P. Exosomal microRNAs as a promising theragnostic tool for essential hypertension. Hypertens Res. 2020;43(1):74–5.

17. Ushanthika T, Smiline Girija AS, Paramasivam A, Priyadharshini JV. An in silico approach towards identification of virulence factors in red complex pathogens targeted by reserpine. Nat Prod Res. 2021;35(11):1893–8.

18. Sukumarar P, Thomas B, Babu S, Oommen S. Clinical profile and outcome of patients with sputum positive Acinetobacter baumannii infection Respiratory infections;2018.

19. Padde JR, Jama SH, Xiaohan L, Mingcheng L. Characteristics of 32 Acinetobacter baumannii isolates co-harboring OXA-Carbapenemases and 16S rRNA methylase gene. Vol. 11, African Journal of Microbiology Research. 2017;110–6.

20. Forman A, Pfoh R, Eddenden A, Howell PL, Nitz M. Synthesis of defined mono-de-N-acetylated β-(1–6)-N-acetyl-d-glucosamine oligosaccharides to characterize PgaB hydrolase activity. Org Biomol Chem. 2019;17(43):9456–66.

21. Geourjon C, Deléage G. SOPMA: significant improvements in protein secondary structure prediction by consensus prediction from multiple alignments. Bioinformatics. 1995;11:681–4.

22. Ramarathinam SH, Ho BK, Dudek NL, Purcell AW. HLA class II immunopeptidomics reveals that co-inherited HLA-allotypes within an extended haplotype can improve proteome coverage for immunosurveillance. Proteomics. 2021:e2000160.

23. Ramsbottom KA, Carr DF, Jones AR, Rigden DJ. Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions. Molecular Immunology. 2018;101:488–99.

24. Ramalingam AK, Selvi SGA, Jayaseelan VP. Targeting prolyl tripeptidyl peptidase from Porphyromonas gingivalis with the bioactive compounds from Rosmarinus officinalis. Asian Biomed . 2019;13(5):197–203.

25. Kumar SP, Girija ASS, Priyadharshini JV. Targeting NM23-H1-mediated inhibition of tumour metastasis in viral hepatitis with bioactive compounds from Ganoderma lucidum: A computational study. Pharmaceutical-sciences. 2020;82(2).

26. Mathivadani V, Smiline AS, Priyadharshini JV. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA-1) with Murraya koengii bio-compounds: An in-silico approach. Acta Virol. 2020;64(1):93–9.

27. Samuel SR, Kuduruthullah S, Khair AMB, Shayeb MA, Elkaseh A, Varma SR. Dental pain, parental SARS-CoV-2 fear and distress on quality of life of 2 to 6 year-old children during COVID-19. Int J Paediatr Dent. 2021;31(3):436–41.

28. A.S.Smiline Girija, KP Suba, G Hariprasad, R Raghu Ramana. A novel study on the
antibacterial effect of the crude squid ink extracts from the Indian squid against four bacterial pathogens isolated from carious dentine. International Journal of Current Microbiology and Applied Sciences. 2014;3(4):904-911 29.

29. Mahapatra S, Chaly PE, Smiline Girija AS. Effectiveness of various disinfection techniques on vegetables and fruits: an in-vitro study. Arch Dent Med Res. 1 (3):1-8

30. Suba KP, Stalin A, Smiline Girija AS, Raguraman R. Homology modelling and docking analysis of prodigiosin from Serratia marcescens. Biotechnology. 55:12897-12902.

31. JV Priyadharsini, J Vijayashree Priyadharsini, A.S Smiline Girija. An insight into the emergence of Acinetobacter baumannii as an oro-dental pathogen and its drug resistance gene profile–An in silico approach. Heliyon 2018; 4: e01051.

32. Jayaseelan VP, Paramasivam A. Emerging role of NET inhibitors in cardiovascular diseases. Hypertens Res. 2020;43(12):1459–61.

33. Iswarya Jaisankar A, Smiline Girija AS, Gunasekaran S, Vijayashree Priyadharsini J. Molecular characterisation of csgA gene among ESBL strains of A. baumannii and targeting with essential oil compounds from Azadirachta indica. Journal of King Saud University - Science. 2020;32 (8):3380–7.

34. Girija AS. Fox3 (+) CD25 (+) CD4 (+) T-regulatory cells may transform the nCoV’s final destiny to CNS! Journal of Medical Virology. 2020:9:5623-27.